Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Wetlands enforcement action for architectural and construction building products company
Successfully represented U.S. and Canadian architectural and construction building products company with regard to a wetlands enforcement action more
Acquisition for a developer of commercial and residential properties
The firm served as lead counsel in the acquisition for a developer of commercial and residential properties. more
Successful litigation of condominium construction defect claims
Represented the plaintiff Trillium Ridge Condominium Association in pursuing claims for the defective design and construction of six high-end more
Sale of interest in a joint venture
Represented Miller Industries, Inc. (NYSE: MLR) in its March 2014 sale of all of its interest in a manufacturing joint venture to its joint venture more